SPARC-like1 mRNA is overexpressed in human uterine leiomyoma

Mencalha, André Luiz; Levinsphul, Alexandre; Deterling, Louise Calil; Pizzatti, Luciana; Abdelhay, Eliana

doi:10.3892/mmr.1.4.571

Cited by 6 publications

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2A ). In addition, the associations identified in the present review, between SPARCL1 and invasiveness, metastasis and drug resistance of cancer, were consistent with previous studies ( Table I )( 9 – 16 , 18 – 26 ). Furthermore, analysis indicated that SPARCL1 may participate in cancer development and progression, in 9 biological processes (P<0.001) including cell viability, cell cycle, migration and adhesion ( Fig.…”

Section: Sparcl1 Contributes To Tumor Development and Progressionsupporting

confidence: 92%

Associations of tumor suppressor SPARCL1 with cancer progression and prognosis

Liu

Yang

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

SPARC-like protein 1 (SPARCL1), a member of the family of secreted proteins which is acidic and rich in cysteine, is a potential tumor suppressor gene in most types of tumor. A systemic review and bioinformatics analysis was carried out to determine the associations between SPARCL1 and tumor progression and clinical factors. Downregulation of SPARCL1, thought to be regulated by epigenetic modifications including DNA methylation, serves important functions in tumor progression and development, with its regulatory functions on cell viability, migration, invasion, cell adhesion and drug resistance. Downregulation of SPARCL1 was markedly associated with a poor overall survival rate of patients with one of ≥7 solid tumors and predicted increased mortality in patients with one of ≥4 distinct tumor types. The present review indicated that SPARCL1 may be a therapeutic target for cancer treatment and a biomarker to determine prognosis.

show abstract

Section: Sparcl1 Contributes To Tumor Development and Progressionsupporting

confidence: 92%

Associations of tumor suppressor SPARCL1 with cancer progression and prognosis

Liu

Yang

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…Particularly, growing evidence shows that SPARCL1 often presents a reduced or absent expression pattern in a variety of human tumor tissues (Bendik et al, 1998;Nelson et al, 1998;Isler et al, 2004;Esposito et al, 2007;Zaravinos et al, 2011;Hurley et al, 2012;Li et al, 2012). However, several studies have also found that an increased expression of SPARCL1 in a few of other type of human tumors derived from liver (Lau et al, 2006), uterus (Mencalha et al, 2008), and colon and rectum (Zhang et al, 2011;Hu et al, 2012). All these conflicting findings suggest that SPARCL1 is indeed implicated in human cancer development and progression, but its expression pattern may be in a tissue-specific manner.…”

Section: Discussionmentioning

confidence: 99%

Clinicopathological Significance of Reduced SPARCL1 Expression in Human Breast Cancer

Cao¹,

Kuo²,

Zhu³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Secreted protein acidic and rich in cysteines-like protein 1 (SPARCL1), an extracellular matrix glycoprotein, has been implicated in the pathogenesis of several disorders including cancer. However, little is known about the expression and significance of SPARCL1 in human breast cancer. The aim of this study was to determine the expression pattern and clinicopathological significance of SPARCL1 in a Chinese breast cancer cohort. mRNA and protein expression of SPARCL1 in human breast cancer cell lines and breast cancer tissues was detected using the reverse transcription-polymerase chain reaction, real-time quantitative PCR, and Western blotting, respectively. Immunostaining of SPARCL1 in 282 Chinese breast cancer samples was examined and associations with clinicopathological parameters were analyzed. Compared to the positive expression in immortalized human breast epithelial cells, SPARCL1 was nearly absent in human breast cancer cell lines. Similarly, a significantly reduced expression of SPARCL1 was observed in human breast cancer tissues compared to that in normal breast epithelial tissues, for both mRNA and protein levels (P < 0.001). Immunohistochemical analysis showed that strong cytoplasmic immunostaining of SPARCL1 was observed in almost all normal breast samples (43/45) while moderate and strong immunostaining of SPARCL1 was only detected in 191 of 282 (67.7%) breast cancer cases. Moreover, down-regulation of SPARCL1 was significantly correlated with lymphatic metastasis (P = 0.020) and poor grade (P = 0.044). In conclusion, SPARCL1 may be involved in the breast tumorigenesis and serve as a promising target for therapy of breast cancer.

show abstract

“…SPARCL1 has been described in many cellular processes 14, including development, tissue regeneration, and cancer, though data concerning it in cancer have been controversial 15–17. In addition, its role in GC is still unknown.…”

Section: Introductionmentioning

confidence: 99%